Ref ID: 18734
Author:
A. Atalay, M.D – Assistant Professor, G. Metan, MD (Doctor of Medicine) – Associate Professor, A. N. Koc, M.D – Professor, L. G. Kaynar, M.D – Assistant Professor, H. Buyukoglan, M.D – Assistant Professor, I. Bozkurt, M.D – Infectious Diseases Specia
Author address:
Erciyes Univ., Kayseri, Turkey.
Full conference title:
52nd Annual ICAAC
Date: 9 September 2014
Abstract:
Background: The aim of this study is to assess the utility of (1,3)-beta-D-glucan (BDG) assay in bronchoalveolar lavage (BAL) fluid for the diagnosis of invasive aspergillosis (IA). Patients and methods: Forty-five patients at high risk for IA and underwent bronchoscopy were included in the study. Twenty-three of the patients had hematological malignancies. 15 out of 45 patients had probabe IA based on European Organization for Research and Treatment of Cancer and the Mycoses Study Group criteria (independent of BDG results). Serum samples and BAL fluid were tested for BDG (Fungitell; Associates of Cape Cod Inc, Falmouth, MA,USA) according to the manufacturers’ recommendations. Results: The sensitivity of BDG in BAL fluid was 93.3% (95% Confidence interval (CI), 66-99.6), specificity was 53.3% (95% CI,34.6-71.2), positive predictive value (PPV) was 50%, and negative predictive value (NPV) was 94.1% at a cutoff value of 80 pg/mL, respectively. An Receiver operating characteristics (ROC) curve was constructed to define the optimum BAL BDG cutoff value for the diagnosis of IA (Figure 1). The area under the ROC curve was 0.81 (95% CI, 0.66-0.91; p<0.001). At a cutoff value of 150 pg/mL, the sensitivity was 80% (95% CI, 51.9- 95.4), specificity was 76.7% (95% CI, 57.7- 90.0), PPV was 63.2%, and NPV was 88.5%. Conclusion: Detection of BDG in BAL fluid seems to be a promising tool to rule out IA in high risk patients based on the high NPV.
Abstract Number: M-1701
Conference Poster: y
Conference Year: 2012
Link to conference website: NULL
New link: NULL
Conference abstracts, posters & presentations
-
Title
Author
Year
Number
Poster
-
v
Teclegiorgis Gebremariam [MS]1, Yiyou Gu [PhD]1, Sondus Alkhazraji [PhD]1, Jousha Quran1, Laura K. Najvar [BS]2, Nathan P. Wiederhold [PharmD]2, Thomas F. Patterson [MD]2, Scott G. Filler [MD]1,3, David A. Angulo (MD)4, Ashraf S. Ibrahim [PhD]1,3*,
2024
91
n/a
-
v
Ruta Petraitiene (US)
2024
90
n/a
-
v
Fabio Palmieri (CH), Junier Pilar
2024
89
n/a
-
v
Evelyne Côté (CA)
2024
88
n/a
-
v
Eliane Vanhoffelen (BE)
2024
87
n/a
-
v
Teclegiorgis Gebremariam, Yiyou Gu, Eman Youssef, Sondus Alkhazraji, Joshua Quran, Nathan P. Wiederhold, Ashraf S. Ibrahim
2024
86
n/a
-
v
Thomas Orasch (DE)
2024
85
n/a
-
v
Julien Alex, Katherine González, Gauri Gangapurwala, Antje Vollrath, Zoltán Cseresnyés, Christine Weber, Justyna A. Czaplewska, Stephanie Hoeppener, Carl-Magnus Svensson, Thomas Orasch, Thorsten Heinekamp, Carlos Guerrero-Sánchez, Marc Thilo Figge, Ulrich S. Schubert, Axel A. Brakhage
2024
84
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
83
n/a
-
v
Vasireddy Teja, Bibhuti Saha Hod, Soumendranath Haldar (IN)
2024
82
n/a